We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

FDA Approves ACTEMRA® for the Treatment of Moderately to Severely Active Rheumatoid Arthritis

News   Jan 11, 2010

 
FDA Approves ACTEMRA® for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
 
 
Advertisement
 

RELATED ARTICLES

Uncovering a Novel Mechanism for Disposing of Misfolded Proteins

News

About 30 years ago, Dr. Richard Sifers set out on a journey to discover why people with a rare condition known as alpha1-antitrypsin (AAT) deficiency present with high variation in the severity of liver disease. His journey led him to the discovery of fundamental underpinnings of this condition and, unexpectedly, to uncovering a novel cellular mechanism for disposing of misfolded proteins.

READ MORE

Neuropilin-1 Identified as a Facilitator for SARS-CoV-2 Entry Into Cells’ Interior

News

The coronavirus SARS-CoV-2 is known to infect cells via the receptor ACE2. An international research team under German-Finnish coordination has now identified neuropilin-1 as a factor that can facilitate SARS-CoV-2 entry into the cells’ interior.

READ MORE

UK Researchers Set To Explore Human Challenge Studies for COVID-19 Vaccine Development

News

Researchers are set to explore a human challenge study with the virus that causes COVID-19, the first such study anywhere in the world.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE